about
DNA and the chromosome - varied targets for chemotherapyAlkaloids from marine invertebrates as important leads for anticancer drugs discovery and developmentVon Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerPharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer CellsActivity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasClinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effectsTrabectedin is a promising antitumour agent for synovial sarcoma.A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia.Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
P2860
Q24792540-16AE1AF9-A4F3-4C35-834C-10E446203B24Q27012072-EBECCBBE-BA6A-4F87-A991-F7B51D29EAFFQ33377399-4EF39127-5616-41B1-9123-89781ADA5835Q33392364-8B9B151D-EFA1-499A-8AA0-60068C85E3C1Q34413670-922FCE80-936A-4DAC-AD11-E4BD005AD0E7Q36614276-6405B30B-8284-4803-8A59-CFDCC8576F04Q37413497-04BED340-355E-47B4-83CA-DF8148A64112Q37747771-ED0F2E64-3B2E-4D11-A9E9-C9075356AA94Q37969213-8065103A-1A62-4E45-B57A-A973A586601CQ38337608-95B1C1A7-1C6A-4AEC-AF3B-2F648E0CED76Q38611141-0EB65CA6-7FC7-4725-BD1D-FD91F4B2F921Q38778290-8E9A3090-76C6-4C44-90C7-EB60FC47E7EAQ39106004-3F1055E5-6473-409F-B12F-EB28068F82D2Q49605810-01C4F6AA-4C54-465F-8D4B-F29EAD0A55C9
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Unique features of the mode of action of ET-743.
@ast
Unique features of the mode of action of ET-743.
@en
Unique features of the mode of action of ET-743.
@nl
type
label
Unique features of the mode of action of ET-743.
@ast
Unique features of the mode of action of ET-743.
@en
Unique features of the mode of action of ET-743.
@nl
prefLabel
Unique features of the mode of action of ET-743.
@ast
Unique features of the mode of action of ET-743.
@en
Unique features of the mode of action of ET-743.
@nl
P2093
P50
P1433
P1476
Unique features of the mode of action of ET-743.
@en
P2093
Emanuela Galliera
Eugenio Erba
Giovanna Damia
Glynn T Faircloth
José Jimeno
Roberto Mantovani
P304
P356
10.1634/THEONCOLOGIST.7-3-210
P577
2002-01-01T00:00:00Z